Inflammasome signaling affects anxiety- and depressive-like behavior and gut microbiome composition

Molecular Psychiatry

Volumn 21, Issue 6, 2016, Pages 797-805

  Wong, M L ^a,b   Inserra, A ^a,b   Lewis, M D ^a,b   Mastronardi, C A ^c   Leong, L ^a,d   Choo, J ^a,d   Kentish, S ^e   Xie, P ^f   Morrison, M ^g   Wesselingh, S L ^a,d   Rogers, G B ^a,d   Licinio, J ^a,b  

^a SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

^c Biology and Environment   (Australia)

^d FLINDERS UNIVERSITY   (Australia)

^e UNIVERSITY OF ADELAIDE   (Australia)

^f CHONGQING MEDICAL UNIVERSITY   (China)

^g UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; MINOCYCLINE; RNA 16S; CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CHRONIC STRESS; CONTROLLED STUDY; ELEVATED PLUS MAZE TEST; ENZYME ACTIVITY; ENZYME INHIBITION; FORCED SWIM TEST; IMMOBILIZATION STRESS; IMMUNOMODULATION; INTESTINE FLORA; LOCOMOTION; MAJOR DEPRESSION; MALE; MARBLE BURYING TEST; MOUSE; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; NOVELTY SUPPRESSED FEEDING TEST; OPEN FIELD TEST; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RESPIROMETRY; RNA ANALYSIS; ROTAROD TEST; SIGNAL TRANSDUCTION; SUCROSE PREFERENCE TEST; ANIMAL; ANIMAL BEHAVIOR; ANXIETY DISORDER; BRAIN; C57BL MOUSE; COMPLICATION; DEPRESSION; IMMUNOLOGY; INFLAMMATION; MENTAL STRESS; METABOLISM; MICROBIOLOGY; MICROFLORA; PHYSIOLOGY;

ANIMALS; ANXIETY; ANXIETY DISORDERS; BEHAVIOR, ANIMAL; BRAIN; CASPASE 1; CYTOKINES; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; GASTROINTESTINAL MICROBIOME; INFLAMMASOMES; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MICROBIOTA; NEUROIMMUNOMODULATION; SIGNAL TRANSDUCTION; STRESS, PSYCHOLOGICAL;

EID: 84964389097     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2016.46     Document Type: Article

References (70)

1. Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012; 36: 764-785
2. Licinio J, Wong ML. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry 1999; 4: 317-327
3. Mikova O, Yakimova R, Bosmans E, Kenis G, Maes M. Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol 2001; 11: 203-208
4. Kokai M, Kashiwamura S, Okamura H, Ohara K, Morita Y. Plasma interleukin-18 levels in patients with psychiatric disorders. J Immunother 2002; 25(Suppl 1): S68-S71
5. Wong ML, Dong C, Maestre-Mesa J, Licinio J. Polymorphisms in inflammationrelated genes are associated with susceptibility to major depression and antidepressant response. Mol Psychiatry 2008; 13: 800-812
6. Wong ML, Licinio J. Localization of interleukin 1 type I receptor mRNA in rat brain. Neuroimmunomodulation 1994; 1: 110-115
7. Wong ML, Bongiorno PB, Rettori V, McCann SM, Licinio J. Interleukin (IL) 1beta, IL-1 receptor antagonist, IL-10, and IL-13 gene expression in the central nervous system and anterior pituitary during systemic inflammation: pathophysiological implications. Proc Natl Acad Sci USA 1997; 94: 227-232
8. Licinio J, Wong ML, Gold PW. Localization of interleukin-1 receptor antagonist mRNA in rat brain. Endocrinology 1991; 129: 562-564
9. Goshen I, Yirmiya R. Interleukin-1 (IL-1): a central regulator of stress responses. Front Neuroendocrinol 2009; 30: 30-45
10. Goshen I, Kreisel T, Ben-Menachem-Zidon O, Licht T, Weidenfeld J, Ben-Hur T, et al. Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry 2008; 13: 717-728
11. Udina M, Moreno-Espana J, Capuron L, Navines R, Farre M, Vieta E, et al. Cytokineinduced depression: current status and novel targets for depression therapy. CNS Neurol Disord Drug Targets 2014; 13: 1066-1074
12. Leemans JC, Cassel SL, Sutterwala FS. Sensing damage by the NLRP3 inflammasome. Immunol Rev 2011; 243: 152-162
13. Franchi L, Eigenbrod T, Munoz-Planillo R, Nunez G. The inflammasome: a caspase-1-Activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 2009; 10: 241-247
14. Alcocer-Gomez E, de Miguel M, Casas-Barquero N, Nunez-Vasco J, Sanchez-Alcazar JA, Fernandez-Rodriguez A, et al. NLRP3 inflammasome is activated in mononuclear blood cells from patients with major depressive disorder. Brain Behav Immun 2014; 36: 111-117
15. Iwata M, Ota KT, Duman RS. The inflammasome: pathways linking psychological stress, depression, and systemic illnesses. Brain Behav Immun 2013; 31: 105-114
16. Garrido-Mesa N, Zarzuelo A, Galvez J. What is behind the non-Antibiotic properties of minocycline?. Pharmacol Res 2013; 67: 18-30
17. Molina-Hernandez M, Tellez-Alcantara NP, Perez-Garcia J, Olivera-Lopez JI, Jaramillo-Jaimes MT. Antidepressant-like actions of minocycline combined with several glutamate antagonists. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 380-386
18. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000; 6: 797-801
19. Ahuja M, Bishnoi M, Chopra K. Protective effect of minocycline, a semi-synthetic second-generation tetracycline against 3-nitropropionic acid (3-NP)-induced neurotoxicity. Toxicology 2008; 244: 111-122
20. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 2001; 98: 14669-14674
21. Molina-Hernandez M, Tellez-Alcantara NP, Perez-Garcia J, Olivera-Lopez JI, Jaramillo-Jaimes MT. Desipramine or glutamate antagonists synergized the antidepressant-like actions of intra-nucleus accumbens infusions of minocycline in male Wistar rats. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1660-1666
22. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM. The promise of minocycline in neurology. Lancet Neurol 2004; 3: 744-751
23. Li P, Allen H, Banerjee S, Franklin S, Herzog L, Johnston C, et al. Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell 1995; 80: 401-411
24. Mastronardi C, Whelan F, Yildiz OA, Hannestad J, Elashoff D, McCann SM, et al. Caspase 1 deficiency reduces inflammation-induced brain transcription. Proc Natl Acad Sci USA 2007; 104: 7205-7210
25. Sommer F, Backhed F. The gut microbiota-masters of host development and physiology. Nat Rev Microbiol 2013; 11: 227-238
26. Tillisch K, Labus J, Kilpatrick L, Jiang Z, Stains J, Ebrat B, et al. Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology 2013; 144: 1394-1401, e1391-1394
27. Cryan JF, Dinan TG. Mind-Altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 2012; 13: 701-712
28. Foster JA, McVey Neufeld KA. Gut-brain axis: how the microbiome influences anxiety and depression. Trends Neurosci 2013; 36: 305-312
29. Park AJ, Collins J, Blennerhassett PA, Ghia JE, Verdu EF, Bercik P, et al. Altered colonic function and microbiota profile in a mouse model of chronic depression. Neurogastroenterol Motil 2013; 25: 733-e575
30. Desbonnet L, Clarke G, Traplin A, O'Sullivan O, Crispie F, Moloney RD, et al. Gut microbiota depletion from early adolescence in mice: Implications for brain and behaviour. Brain Behav Immun 2015; 48: 165-173
31. Lawson MA, McCusker RH, Kelley KW. Interleukin-1 beta converting enzyme is necessary for development of depression-like behavior following intracerebroventricular administration of lipopolysaccharide to mice. J Neuroinflammation 2013; 10: 54
32. Burgess W, Gheusi G, Yao J, Johnson RW, Dantzer R, Kelley KW. Interleukin-1betaconverting enzyme-deficient mice resist central but not systemic endotoxininduced anorexia. Am J Physiol 1998; 274(6 Pt 2): R1829-R1833
33. Brinkman BM, Hildebrand F, Kubica M, Goosens D, Del Favero J, Declercq W, et al. Caspase deficiency alters the murine gut microbiome. Cell Death Dis 2011; 2: e220
34. McIlwain KL, Merriweather MY, Yuva-Paylor LA, Paylor R. The use of behavioral test batteries: effects of training history. Physiol Behav 2001; 73: 705-717
35. Jervis-Bardy J, Leong LE, Marri S, Smith RJ, Choo JM, Smith-Vaughan HC, et al. Deriving accurate microbiota profiles from human samples with low bacterial content through post-sequencing processing of Illumina MiSeq data. Microbiome 2015; 3: 19
36. Kinnear PR, Gray CD. PASW Statistics 17 Made Simple (Replaces SPSS Statistics 17)1st ednPsychology Press: East Sussex, 2010
37. Rogers GB, Shaw D, Marsh RL, Carroll MP, Serisier DJ, Bruce KD. Respiratory microbiota: addressing clinical questions, informing clinical practice. Thorax 2015; 70: 74-81
38. Deacon RM. Digging and marble burying in mice: simple methods for in vivo identification of biological impacts. Nat Protoc 2006; 1: 122-124
39. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87: 2095-2147
40. Koo JW, Duman RS. IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci USA 2008; 105: 751-756
41. Koo JW, Duman RS. Interleukin-1 receptor null mutant mice show decreased anxiety-like behavior and enhanced fear memory. Neurosci Lett 2009; 456: 39-43
42. Homsi S, Federico F, Croci N, Palmier B, Plotkine M, Marchand-Leroux C, et al. Minocycline effects on cerebral edema: relations with inflammatory and oxidative stress markers following traumatic brain injury in mice. Brain Res 2009; 1291: 122-132
43. Kim SS, Kong PJ, Kim BS, Sheen DH, Nam SY, Chun W. Inhibitory action of minocycline on lipopolysaccharide-induced release of nitric oxide and prostaglandin E2 in BV2 microglial cells. Arch Pharm Res 2004; 27: 314-318
44. Zhang L, Shirayama Y, Shimizu E, Iyo M, Hashimoto K. Protective effects of minocycline on 3, 4-methylenedioxymethamphetamine-induced neurotoxicity in serotonergic and dopaminergic neurons of mouse brain. Eur J Pharmacol 2006; 544: 1-9
45. Arakawa S, Shirayama Y, Fujita Y, Ishima T, Horio M, Muneoka K, et al. Minocycline produced antidepressant-like effects on the learned helplessness rats with alterations in levels of monoamine in the amygdala and no changes in BDNF levels in the hippocampus at baseline. Pharmacol Biochem Behav 2012; 100: 601-606
46. Miyaoka T, Wake R, Furuya M, Liaury K, Ieda M, Kawakami K, et al. Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2012; 37: 222-226
47. Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. Minocycline as adjunctive therapy for schizophrenia: an open-label study. Clin Neuropharmacol 2008; 31: 287-292
48. Chaudhry IB, Hallak J, Husain N, Minhas F, Stirling J, Richardson P, et al. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol 2012; 26: 1185-1193
49. Liu F, Guo X, Wu R, Ou J, Zheng Y, Zhang B, et al. Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. Schizophr Res 2014; 153: 169-176
50. Yang T, Santisteban MM, Rodriguez V, Li E, Ahmari N, Carvajal JM, et al. Gut dysbiosis is linked to hypertension. Hypertension 2015; 65: 1331-1340
51. Jeffery IB, O'Toole PW, Ohman L, Claesson MJ, Deane J, Quigley EM, et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 2012; 61: 997-1006
52. Harrison DG. The immune system in hypertension. Trans Am Clin Climatol Assoc 2014; 125: 130-138, discussion 138-140
53. Akiho H, Ihara E, Nakamura K. Low-grade inflammation plays a pivotal role in gastrointestinal dysfunction in irritable bowel syndrome. World J Gastrointest Pathophysiol 2010; 1: 97-105
54. Riedel CU, Foata F, Philippe D, Adolfsson O, Eikmanns BJ, Blum S. Antiinflammatory effects of bifidobacteria by inhibition of LPS-induced NF-kappaB activation. World J Gastroenterol 2006; 12: 3729-3735
55. Koo JW, Russo SJ, Ferguson D, Nestler EJ, Duman RS. Nuclear factor-kappaB is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proc Natl Acad Sci USA 2010; 107: 2669-2674
56. Ravussin Y, Koren O, Spor A, LeDuc C, Gutman R, Stombaugh J, et al. Responses of gut microbiota to diet composition and weight loss in lean and obese mice. Obesity 2012; 20: 738-747
57. Zenewicz LA, Yin X, Wang G, Elinav E, Hao L, Zhao L, et al. IL-22 deficiency alters colonic microbiota to be transmissible and colitogenic. J Immunol 2013; 190: 5306-5312
58. Miettinen M, Pietila TE, Kekkonen RA, Kankainen M, Latvala S, Pirhonen J, et al. Nonpathogenic Lactobacillus rhamnosus activates the inflammasome and antiviral responses in human macrophages. Gut Microbes 2012; 3: 510-522
59. Anisman H, Merali Z, Poulter MO, Hayley S. Cytokines as a precipitant of depressive illness: animal and human studies. Curr Pharm Des 2005; 11: 963-972
60. Shintani F, Nakaki T, Kanba S, Sato K, Yagi G, Shiozawa M, et al. Involvement of interleukin-1 in immobilization stress-induced increase in plasma adrenocorticotropic hormone and in release of hypothalamic monoamines in the rat. J Neurosci 1995; 15(3 Pt 1): 1961-1970
61. Anhe FF, Roy D, Pilon G, Dudonne S, Matamoros S, Varin TV, et al. A polyphenolrich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice. Gut 2015; 64: 872-883
62. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, et al. Cross-Talk between Akkermansia muciniphila and intestinal epithelium controls dietinduced obesity. Proc Natl Acad Sci USA 2013; 110: 9066-9071
63. Shin NR, Lee JC, Lee HY, Kim MS, Whon TW, Lee MS, et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 2014; 63: 727-735
64. Biddle A, Stewart L, Blanchard J, Leschine S. Untangling the genetic basis of fibrolytic specialization by Lachnospiraceae and Ruminococcaceae in diverse gut communities. Diversity 2013; 5: 627-640
65. Modi SR, Collins JJ, Relman DA. Antibiotics and the gut microbiota. J Clin Invest 2014; 124: 4212-4218
66. Genton L, Cani PD, Schrenzel J. Alterations of gut barrier and gut microbiota in food restriction, food deprivation and protein-energy wasting. Clin Nutr 2015; 34: 341-349
67. Hanell A, Marklund N. Structured evaluation of rodent behavioral tests used in drug discovery research. Front Behav Neurosci 2014; 8: 252
68. Zhu S, Shi R, Wang J, Wang JF, Li XM. Unpredictable chronic mild stress not chronic restraint stress induces depressive behaviours in mice. Neuroreport 2014; 25: 1151-1155
69. Strekalova T, Couch Y, Kholod N, Boyks M, Malin D, Leprince P, et al. Update in the methodology of the chronic stress paradigm: internal control matters. Behav Brain Funct 2011; 7: 9
70. Zheng P, Zeng B, Zhou C, Liu M, Xu X, Zeng L, et al. Altered gut microbiome induces depression-like behaviors in a pathway that is mediated through the host?s metabolism. Mol Psychiatry 2016; doi: 10.1038/mp.2016.44 (in press